Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Amgen
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia)
To evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab administered every month (QM) compared with placebo QM on percent change from baseline in low-density lipoprotein cholesterol (LDL-C)...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 710, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, infliximab, in patients with moderate or severe rheumatoid arthritis (RA). This study will assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine. Este ensayo ha sido diseñado para determinar los efectos del cuerpo humano sobre el fármaco experimental, ABP 710, así como los efecto del cuerpo sobre el fármaco en investigación después de haberlo administrado, y verificar si son comparables a los efectos observados con el fármaco aprobado, infliximab, en pacientes con artritis reumatoide (AR) de moderada a grave
The primary objective for this study is to assess the efficacy of ABP 710 compared with US-licensed infliximab (infliximab). El objetivo principal de este estudio es evaluar la eficacia de ABP 7...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
AMGEN ASPECCT : Essai de phase 3 randomisé comparant l’efficacité et la tolérance du panitumumab et du cétuximab, chez des patients ayant un cancer colorectal métastatique et non porteur d’une mutation du gène KRAS. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité et la tolérance du panitumumab (Vectibix) à celle du cétuximab (Erbitux), chez des patients ayant un cancer colorectal métastatique et dont la tume...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
Amgen 2000225 : Essai de phase 2 randomisé, évaluant l'efficacité de l’association paclitaxel, à AMG 706 ou au bévacizumab, en traitement de 1ère ligne, chez des patientes ayant un cancer du sein HER2 négatif, en récidive locale ou métastatique [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized phase 2 trial of double-blind, placebo controlled AMG 706 in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with HER...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe rheumatoid arthritis
The primary objective for this study is to assess the efficacy of ABP 501 compared with adalimumab.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates
To determine the effectiveness of AMG 162 in reducing urinary N-telopeptide (uNTx) below 50 nM BCE / mM creatinine in advanced cancer subjects with bone metastases (including multiple myeloma subjects...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 50 response at week 12.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Amgen, Inc
Update Il y a 4 ans
Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease
To describe histomorphometric parameters of bone turnover in dialysis subjects with high turnover renal osteodystrophy during treatment with Sensipar®/Mimpara® with or without concomitant vitamin D st...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Amgen
Update Il y a 4 ans
Amgen 20060439 : Essai de phase 2 randomisé, en double aveugle, évaluant l'efficacité et la tolérance de l'AMG 386 associé au cisplatine et à la capécitabine chez des patients ayant un cancer gastrique métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized, double blind, multi-center, phase 2 study to estimate the efficacy and evaluate the safety and tolerability of cisplatin & capecitabine (CX) in combination with AMG 386 or placebo in sub...
Country
France
organs
Estomac
,
Oesophage
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Amgen, Inc
Update Il y a 4 ans
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates
To evaluate the change in total hip Bone Mineral Density (BMD) at 12 months in postmenopausal women transitioning from previous daily or weekly bisphosphonate therapy to denosumab 60 mg SC Q6M compare...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next